Who are CPA's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): D-cure, VEC, GSK208141 vaccine, CancerVax vaccine (CANVAXIN), HSPPC-96 or Oncophage, NeuVax™ vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cpa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CPA — Competitive Intelligence Brief

CPA (CPA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Therapeutic cancer vaccine. Area: Oncology.

marketed Therapeutic cancer vaccine Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CPA (CPA) — ImmunoVaccine Technologies, Inc. (IMV Inc.). CPA is a cancer immunotherapy vaccine that stimulates the immune system to recognize and attack cancer cells by presenting tumor-associated antigens.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CPA TARGET	CPA	ImmunoVaccine Technologies, Inc. (IMV Inc.)	marketed	Therapeutic cancer vaccine
D-cure	D-cure	KU Leuven	marketed	Therapeutic cancer vaccine
VEC	VEC	Centre Leon Berard	marketed	Therapeutic cancer vaccine
GSK208141 vaccine	GSK208141 vaccine	GlaxoSmithKline	phase 3	Therapeutic cancer vaccine
CancerVax vaccine (CANVAXIN)	CancerVax vaccine (CANVAXIN)	CancerVax Corporation	phase 3	Therapeutic cancer vaccine	MAGE-1, MAGE-3 (melanoma-associated antigens)
HSPPC-96 or Oncophage	HSPPC-96 or Oncophage	Agenus Inc.	phase 3	Autologous therapeutic cancer vaccine	Tumor-associated antigens presented via Hsp96 complexes
NeuVax™ vaccine	NeuVax™ vaccine	Galena Biopharma, Inc.	phase 3	Therapeutic cancer vaccine	HER2 (human epidermal growth factor receptor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Therapeutic cancer vaccine class)

GlaxoSmithKline · 2 drugs in this class
Green Cross Corporation · 2 drugs in this class
Chiang Mai University · 1 drug in this class
Chiltern Pesquisa Clinica Ltda · 1 drug in this class
GERCOR - Multidisciplinary Oncology Cooperative Group · 1 drug in this class
Galena Biopharma, Inc. · 1 drug in this class
Genocea Biosciences, Inc. · 1 drug in this class
ImmunoVaccine Technologies, Inc. (IMV Inc.) · 1 drug in this class
Istituto Oncologico Veneto IRCCS · 1 drug in this class
KU Leuven · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CPA — Competitive Intelligence Brief. https://druglandscape.com/ci/cpa. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab